Spotlight on eltrombopag in the treatment of children with chronic immune thrombocytopenia

Pediatric data on the use of thrombopoietin receptor agonists are fairly limited. The recent approval of eltrombopag by the US Food and Drug Administration for children aged ≥1 year, based on data from two randomized, placebo-controlled clinical trials, may lead to the increased use of this drug in...

Descripción completa

Detalles Bibliográficos
Autor principal: Lambert, Michele P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683296/
https://www.ncbi.nlm.nih.gov/pubmed/29388634
http://dx.doi.org/10.2147/PHMT.S90688
_version_ 1783278253756121088
author Lambert, Michele P
author_facet Lambert, Michele P
author_sort Lambert, Michele P
collection PubMed
description Pediatric data on the use of thrombopoietin receptor agonists are fairly limited. The recent approval of eltrombopag by the US Food and Drug Administration for children aged ≥1 year, based on data from two randomized, placebo-controlled clinical trials, may lead to the increased use of this drug in clinical practice, and therefore, it is important to have a basic understanding of the biology, pharmacokinetics, safety, and efficacy of the medication.
format Online
Article
Text
id pubmed-5683296
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-56832962018-01-31 Spotlight on eltrombopag in the treatment of children with chronic immune thrombocytopenia Lambert, Michele P Pediatric Health Med Ther Review Pediatric data on the use of thrombopoietin receptor agonists are fairly limited. The recent approval of eltrombopag by the US Food and Drug Administration for children aged ≥1 year, based on data from two randomized, placebo-controlled clinical trials, may lead to the increased use of this drug in clinical practice, and therefore, it is important to have a basic understanding of the biology, pharmacokinetics, safety, and efficacy of the medication. Dove Medical Press 2016-06-08 /pmc/articles/PMC5683296/ /pubmed/29388634 http://dx.doi.org/10.2147/PHMT.S90688 Text en © 2016 Lambert. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Lambert, Michele P
Spotlight on eltrombopag in the treatment of children with chronic immune thrombocytopenia
title Spotlight on eltrombopag in the treatment of children with chronic immune thrombocytopenia
title_full Spotlight on eltrombopag in the treatment of children with chronic immune thrombocytopenia
title_fullStr Spotlight on eltrombopag in the treatment of children with chronic immune thrombocytopenia
title_full_unstemmed Spotlight on eltrombopag in the treatment of children with chronic immune thrombocytopenia
title_short Spotlight on eltrombopag in the treatment of children with chronic immune thrombocytopenia
title_sort spotlight on eltrombopag in the treatment of children with chronic immune thrombocytopenia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683296/
https://www.ncbi.nlm.nih.gov/pubmed/29388634
http://dx.doi.org/10.2147/PHMT.S90688
work_keys_str_mv AT lambertmichelep spotlightoneltrombopaginthetreatmentofchildrenwithchronicimmunethrombocytopenia

Ejemplares similares